Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors : a systematic review
INTRODUCTION: Immune-related ocular toxicities are uncommon but serious adverse events that may be associated with the use of immune checkpoint inhibitors. The objective of this review is to assess the incidence and risk of ocular toxicities which are potentially immune-related and occur with immune checkpoint treatment of solid tumors. Areas covered: PubMed database has been searched till June 2016. Prospective clinical trials reporting the occurrence of immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors were included. Eleven trials with 4965 participants were included. These studies included one study for ipilimumab and tremelimumab, three studies for nivolumab, five studies for pembrolizumab and one study comparing pembrolizumab to ipilimumab. No atezolizumab studies were included. The most common ocular toxicities reported with these agents included uveitis and dry eyes. Pooled analysis for odds ratio of all-grade immune-related ocular toxicities is 3.40 [95% CI: 1.32-8.71; P = 0.01]. Expert commentary: Despite being uncommon, immune-related ocular toxicities (particularly uveitis and dry eyes) occur with a higher frequency in cancer patients treated immune checkpoint inhibitors compared to those treated with control regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Expert review of anticancer therapy - 17(2017), 4 vom: 04. Apr., Seite 387-394 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abdel-Rahman, Omar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal |
|---|
| Anmerkungen: |
Date Completed 05.06.2017 Date Revised 16.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737140.2017.1296765 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM269682562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM269682562 | ||
| 003 | DE-627 | ||
| 005 | 20231224225026.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737140.2017.1296765 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0898.xml |
| 035 | |a (DE-627)NLM269682562 | ||
| 035 | |a (NLM)28277102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abdel-Rahman, Omar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors |b a systematic review |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.06.2017 | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Immune-related ocular toxicities are uncommon but serious adverse events that may be associated with the use of immune checkpoint inhibitors. The objective of this review is to assess the incidence and risk of ocular toxicities which are potentially immune-related and occur with immune checkpoint treatment of solid tumors. Areas covered: PubMed database has been searched till June 2016. Prospective clinical trials reporting the occurrence of immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors were included. Eleven trials with 4965 participants were included. These studies included one study for ipilimumab and tremelimumab, three studies for nivolumab, five studies for pembrolizumab and one study comparing pembrolizumab to ipilimumab. No atezolizumab studies were included. The most common ocular toxicities reported with these agents included uveitis and dry eyes. Pooled analysis for odds ratio of all-grade immune-related ocular toxicities is 3.40 [95% CI: 1.32-8.71; P = 0.01]. Expert commentary: Despite being uncommon, immune-related ocular toxicities (particularly uveitis and dry eyes) occur with a higher frequency in cancer patients treated immune checkpoint inhibitors compared to those treated with control regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a atezolizumab | |
| 650 | 4 | |a nivolumab | |
| 650 | 4 | |a ocular toxicities | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Oweira, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Petrausch, Ulf |e verfasserin |4 aut | |
| 700 | 1 | |a Helbling, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Mannhart, Meinrad |e verfasserin |4 aut | |
| 700 | 1 | |a Mehrabi, Arianeb |e verfasserin |4 aut | |
| 700 | 1 | |a Schöb, Othmar |e verfasserin |4 aut | |
| 700 | 1 | |a Giryes, Anwar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d 2001 |g 17(2017), 4 vom: 04. Apr., Seite 387-394 |w (DE-627)NLM11982020X |x 1744-8328 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2017 |g number:4 |g day:04 |g month:04 |g pages:387-394 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737140.2017.1296765 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2017 |e 4 |b 04 |c 04 |h 387-394 | ||